Merus

MRUS

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that the conditions, including the minimum tender condition, to the previously announced tender offer (the “Offer”) by Genmab Holding II B.V., a wholly owned subsidiary of Genmab (“Purchaser”), to acquire all the issued and outstanding common shares of Merus N.V. (Nasdaq: MRUS) (“Merus”) for $97 per common share in cash have been satisfied. The transaction meaningfully accelerates Genmab's shift to a whol.

Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to Genmab's EBITDA by end of 2029 COPENHAGEN, Denmark; December 12, 2025 – Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that the conditions, including the minimum tender condition, to the previously announced tender offer (the “Offer”) by Genmab Holding II B.V., a wholly owned subsidiary of Genmab (“Purchaser”), to acquire all the issued and outstanding common shares of Merus N.V.

Bicara Therapeutics (BCAX) is initiated with a Buy rating, driven by promising data for its HNSCC candidate, Ficera. Ficera's Phase 1b results in HPV-negative HNSCC show strong efficacy, outperforming current standards, albeit rival Merus' petosemtamab data is arguably stronger. BCAX benefits from FDA Breakthrough Therapy Designation, robust cash reserves, and potential for blockbuster revenues if successful.

SAN DIEGO and UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Nov. 17, 2025 /PRNewswire/ -- Merus N.V.

The market continues to trade deeper in overbought territory based on most traditional valuation metrics. Most of the gains over the past three years have been driven by tech giants riding the AI Revolution higher. Equities continue to hit all-time highs even the government shut down has nearly hit the one month mark and trade tensions remain between China and the U.S.

– 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed) – 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed)  UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Merus N.V.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Merus N.V. (NasdaqGM: MRUS) to Genmab A/S (NasdaqGS: GMAB). Under the terms of the proposed transaction, shareholders of Merus will receive $97.00 in cash for each share of Merus that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whe.

Media Release COPENHAGEN, Denmark; October 21, 2025 Genmab A/S (Nasdaq: G MAB ) (“Genmab”) announced today that it is commencing, through a wholly owned subsidiary, Genmab Holding II B.V. (“ Purchaser ”), a cash tender offer (the “Offer”) to purchase all of the issued and outstanding common shares (“Common Shares”) of Merus N.V.

- Petosemtamab in combination with FOLFOX /FOLFIRI (1L and 2L mCRC) and as monotherapy (3L+ mCRC), demonstrates antitumor activity and a manageable safety profile

-   Plenary session oral presentation: Friday, October 24 10:00 -11:40 a.m. ET -   Poster presentation on preclinical evaluation of petosemtamab on cancer stem cells: Friday, October 24 12:30-4:00 p.m.